A Aralex Aachen research explorer

June 29, 2026 review Open access

Reshaping the Battlefield: Reprogramming the Melanoma Tumour Microenvironment (TME) by Anti-CTLA-4, Anti-PD-1, and Anti-PD-L1 Monotherapy and Combination Therapy: A Systematic Review and Meta-Analysis of Preclinical and Clinical Evidence

DOI: 10.3390/cells15131182 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 0 stored of 1

References 3

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
2021 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access

68

citations
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
2025 Nature Medicine article Medicine Cancer Immunotherapy and Biomarkers Open access

23

citations
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
2023 Journal for ImmunoTherapy of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access

17

citations

3 results